Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the TQH5528 “Oral STAT6 Degrader” independently developed by the group subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”) has published pre-clinical research data in the form of an oral report (Oral) at the 2026 meeting of the European Respiratory Society (ERS 2026), and simultaneously displayed an electronic poster (e-poster).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.